Wall Street’s Thursday roundup of analyst calls brought a broad set of rating changes, target price revisions and new coverage initiations across technology, industrial, consumer, energy and crypto-linked names.
Goldman Sachs upgraded Sunbelt to buy from neutral, citing “growth improvement.” The bank said the company’s 1Q27 results came in ahead of consensus and that management raised its full-year outlook. Analysts added that negative EPS growth over the past two years had reflected weakness in local U.S. non-residential construction markets, which weighed on revenue and margins.
Wolfe kept Tesla at peer perform while saying the setup for 2027 is improving. In the firm’s view, progress in AI and Autonomy remains the main driver for the stock.
Bernstein downgraded Palo Alto Networks, Okta and SentinelOne to market perform from outperform, largely on valuation grounds. The firm said the shares are trading near fair value, with upside and downside appearing relatively balanced at current levels.
Citizens upgraded J.B. Hunt Transport Services (JBHT) to market outperform from market perform and set a $300 price target. Daiwa reiterated Nvidia at outperform but cut its target price to $245 from $255, saying the near-term issue is supply while long-term demand consistency remains the bigger question.
RBC initiated Kraft Heinz at outperform with a $32 price target, saying the company is well positioned for organic revenue growth. Wells Fargo launched coverage on Core Scientific, TeraWulf, Applied Digital and Hut 8 with overweight ratings, highlighting APLD, WULF and HUT among bitcoin miners.
Barclays reinstated coverage of Paramount Skydance at underweight and Warner Bros Discovery at equal weight. The bank said it is concerned about the prospect of further corporate restructuring and M&A activity, which could leave the investment case for PSKY difficult to pin down.
Raymond James initiated Red Violet (RDVT) at outperform, pointing to a strong fundamental backdrop and growing demand for the company’s identity intelligence offerings. Bank of America reiterated Apple as buy, saying demand for the iPhone 18 Pro and Pro Max should continue to hold up with support from higher carrier subsidies.
Evercore ISI reiterated Alphabet at outperform and raised its price target to $450 from $420. Morgan Stanley initiated SiTime at overweight, arguing that a roughly 13% pullback over the past week created an attractive entry point, and assigned a $730 target price.
Stifel initiated Roivant Sciences at buy with a $51 target price. JPMorgan also launched coverage on Celcuity (CELC) at overweight with a December 2027 target price of $157, citing the long-term potential of Revtorpyk (gedatolisib) in breast cancer treatment.
Rosenblatt initiated Soluna Holdings at buy with a $4 target price. Jefferies started coverage on Alpha Teknova at buy, saying the biotech company is well placed for growth tied to biotech funding, recent commercial investment and its clinical pipeline.
Citi upgraded Haemonetics to buy from neutral, saying the return of the CSL contract in the U.S. market could support organic revenue growth, operating margins and EPS over the next several years. Macquarie upgraded Trip.com to outperform, pointing to international expansion and its premium service offering.
Oppenheimer initiated Kopin at outperform with a $7 price target, while Susquehanna started Honeywell Aerospace at positive, citing revenue growth and margin expansion potential through the end of the decade. Seaport launched Paymentus (PAY) at buy with a $42 target price.
Guggenheim downgraded Lyft to neutral from buy and cut its price target to $16 from $22, citing weaker second-half 2027 volume forecasts and a limited path for near-term catalysts.
Bank of America upgraded HawkEye 360 (HAWK) to buy from neutral, while lowering its price objective to $23 from $34, saying valuation remains attractive. Truist initiated Crescent Energy at buy, noting the stock trades at a discount to peers. JPMorgan also initiated Prelude Therapeutics (PRLD) at overweight with a December 2027 price target of $12.
At the same time, Citi downgraded Boston Scientific to neutral from buy, pointing to rising competition and a recent cyberattack. The bank said the company should be able to work through those issues, but the timeline for recovery is still unclear.
